Healthcare & Life Sciences

First record the service date, reference number, requested action and deadline. Notify the appropriate supervisor and medical-affairs, legal or risk-management unit, and notify any liability insurer as the policy requires. Using institution-authorised methods, preserve the record as it existed when notice arrived: charts, nursing records, consent forms, orders, tests and imaging, rosters, relevant work communications, and electronic access and amendment trails. A PDF export alone is not enough, and patient data should not be removed from authorised systems. Do not delete, overwrite, obliterate or back-date an original entry. A paper-record correction must be signed or sealed and dated at the amendment, with deleted text struck through but still legible; an electronic record must keep the old and new entries distinguishable and retain the user, date and complete audit history. A later addition should be identified as such, use its real entry date and explain why it was added. Next identify whether the matter is civil, criminal or administrative. A qualifying civil medical dispute must first go to the local medical-dispute mediation committee; if suit is filed first, the court must refer it and stay the action during mediation. In a criminal medical-dispute case, the prosecutor or court must, subject to statutory exceptions, refer the case and suspend the investigation or trial. A regulatory inquiry follows the legal basis, capacity, request and deadline in its notice. Without all parties' consent, a mediator's exhortations and a party's regret, apology, adverse statement or concession in mediation may not support evidence or judgment in the case or a related administrative disposition. Pre-existing charts and imaging do not gain that protection merely because they were submitted in mediation. Before responding or appearing, review your procedural capacity, the material and the proposed response with the institution and counsel.

Yes, but classify each operative part of the NHIA letter as a medical-fee review reduction, a contract-management measure, or recovery of an amount already paid; one letter may require different remedy routes. For an ordinary fee reduction, seek NHIA re-examination within 60 days after receipt. If unsuccessful, apply for dispute adjudication within 60 days beginning the day after service of the re-examination decision. A further challenge is a public-law action for payment in the administrative court, without an administrative appeal. For suspension, termination, a tenfold deduction or another contract-management measure, one optional written reconsideration may be requested within 30 days. If it is skipped, dispute adjudication must still be sought within 60 days beginning the day after service of the original decision; if it is used, that 60-day period runs from service of the reconsideration decision. After an adverse dispute decision, file an administrative appeal with the MOHW within 30 days, then any revocation action within the non-extendable two-month period after service of the appeal decision. A clawback of the original medical fees generally proceeds through an action for payment, while suspension, termination or a tenfold deduction proceeds through administrative appeal and revocation litigation. Review does not ordinarily stay enforcement automatically, so a separate stay may be needed. Preserve the letter, envelope and proof of service; match each operative paragraph to its legal basis and shortest deadline before reviewing charts, orders, claims, inspection data and sampling calculations.

Food labels, promotions and advertisements must not be false, exaggerated or misleading, and foods may not claim medical efficacy. Regulators assess the overall message conveyed by names, copy, graphics, images, audio, context, stories, implications, links and placement—not one sentence in isolation. A direct or indirect suggestion that a product can prevent, improve, alleviate, diagnose or treat a disease, syndrome or symptom, reduce a bodily constituent associated with disease, or provide the efficacy attributed to a Chinese medicinal material creates risk. The word "improves" is not decisive by itself; the object and overall message matter. Claims for ordinary foods must fit the permitted nutritional or physiological statements and the product itself, while approved health foods may not exceed their approved health-care effects. Endorsements, before-and-after comparisons, posts, comments, testimonials, educational content and shopping links may all be advertising. Foods for special medical purposes require registration and prescribed labelling of intended users, directions, dosage and warnings; their advertising may not exceed the legally required label content. Consumer advertising of infant and follow-up formula is generally prohibited, as are specified promotions such as samples, gifts and discount vouchers. Article 28(1) violations carry fines of NT$40,000 to NT$4 million, and medical-efficacy claims NT$600,000 to NT$5 million. Advertising fines may repeat until publication stops, with additional orders in serious cases. Label or medical-efficacy violations may also trigger recall and correction or confiscation and destruction under Article 52. Review the creative, landing page, links and placement together before launch.

First identify whether the company is the sponsor or a contract research organization (CRO), and separate an adverse event from a trial-related injury. Under Taiwan GCP, an adverse event need not be causally related to the investigational product. It triggers assessment, documentation and applicable reporting, but does not itself establish liability. Article 47 requires a sponsor to indemnify the investigator or institution against claims arising from the trial or provide liability insurance, except to the extent a claim arises from the investigator's or institution's medical negligence. That exception does not release the hospital: it still owes the required standard of medical care, and the investigator and institution must safely follow the approved protocol and provide adequate care for trial-related adverse events. Reporting depends on actor and event type. The investigator generally reports a serious adverse event immediately to the sponsor and an unexpected serious adverse drug reaction to the IRB; the sponsor then reports qualifying reactions to the authority and continues safety evaluation. The consent form must explain compensation or insurance and may not waive the subject's legal rights or release the investigator, institution, sponsor or their agents. Trial agreements and policies may allocate defence, recovery, costs and coverage internally, but cannot prejudice the subject's statutory rights. Allocation ultimately depends on causation, medical negligence, each party's duties, the agreement and the policy—not merely on the occurrence of an adverse event.